Cargando…
COVID-19 and HIV infection co-pandemics and their impact: a review of the literature
Coronavirus disease 2019 (COVID-19) was first detected in December 2019. In March 2020, the World Health Organization declared COVID-19 a pandemic. People with underlying medical conditions may be at greater risk of infection and experience complications from COVID-19. COVID-19 has the potential to...
Autores principales: | Gatechompol, Sivaporn, Avihingsanon, Anchalee, Putcharoen, Opass, Ruxrungtham, Kiat, Kuritzkes, Daniel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097669/ https://www.ncbi.nlm.nih.gov/pubmed/33952300 http://dx.doi.org/10.1186/s12981-021-00335-1 |
Ejemplares similares
-
Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015) -
Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice
por: Gatechompol, Sivaporn, et al.
Publicado: (2019) -
CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV
por: Han, Win Min, et al.
Publicado: (2018) -
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen, Opass, et al.
Publicado: (2013) -
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)